share_log

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3：募资说明书
美股SEC公告 ·  08/14 12:43

Moomoo AI 已提取核心信息

Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in a previous prospectus dated March 23, 2023, with details from its quarterly report filed on August 13, 2024. The supplement relates to the issuance of 4,776,038 shares of common stock underlying previously issued warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with a last reported sales price of $0.35 per share as of August 12, 2024. The supplement, which includes the attached Quarterly Report, provides updated financial information and should be read in conjunction with the original prospectus. The Quarterly Report details the company's financial position, including a net loss of $14.3 million for the six months ended June 30, 2024, and a working capital deficit of $16.0 million. The company has incurred losses of $139.8 million since its inception and continues to face a high degree of risk. The report also includes unaudited condensed consolidated financial statements and notes, which outline the company's assets, liabilities, stockholders' deficit, and comprehensive loss for the period.
Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in a previous prospectus dated March 23, 2023, with details from its quarterly report filed on August 13, 2024. The supplement relates to the issuance of 4,776,038 shares of common stock underlying previously issued warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with a last reported sales price of $0.35 per share as of August 12, 2024. The supplement, which includes the attached Quarterly Report, provides updated financial information and should be read in conjunction with the original prospectus. The Quarterly Report details the company's financial position, including a net loss of $14.3 million for the six months ended June 30, 2024, and a working capital deficit of $16.0 million. The company has incurred losses of $139.8 million since its inception and continues to face a high degree of risk. The report also includes unaudited condensed consolidated financial statements and notes, which outline the company's assets, liabilities, stockholders' deficit, and comprehensive loss for the period.
Panbela Therapeutics， Inc.于2024年8月13日提交了一份招股说明书补充，以更新和补充2023年3月23日之前的招股说明书中的信息，并包括2024年8月13日提交的季度报告中的详细信息。该补充有关于发行4,776,038股在先发行认股权所依据的普通股的事项。该公司的普通股在OTCQb上以“PBLA”的符号进行报价，截至2024年8月12日，上一个报告的销售价格为每股0.35美元。该补充内容（包括所附的季度报告）提供了更新的财务信息，应与原招股说明书一起阅读。季度报告详细介绍了公司的财务状况，其中包括截至2024年6月30日的六个月的净亏损1430万美元，以及1600万美元的营运资本亏损。自成立以来，该公司已经亏损13980万美元，仍面临高风险。报告还包括未经审计的简明合并财务报表和附注，概述了公司的资产、负债、股东赤字以及期间的综合损失。
Panbela Therapeutics， Inc.于2024年8月13日提交了一份招股说明书补充，以更新和补充2023年3月23日之前的招股说明书中的信息，并包括2024年8月13日提交的季度报告中的详细信息。该补充有关于发行4,776,038股在先发行认股权所依据的普通股的事项。该公司的普通股在OTCQb上以“PBLA”的符号进行报价，截至2024年8月12日，上一个报告的销售价格为每股0.35美元。该补充内容（包括所附的季度报告）提供了更新的财务信息，应与原招股说明书一起阅读。季度报告详细介绍了公司的财务状况，其中包括截至2024年6月30日的六个月的净亏损1430万美元，以及1600万美元的营运资本亏损。自成立以来，该公司已经亏损13980万美元，仍面临高风险。报告还包括未经审计的简明合并财务报表和附注，概述了公司的资产、负债、股东赤字以及期间的综合损失。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间